253 related articles for article (PubMed ID: 19043921)
21. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A
J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
Semaine W; Johar M; Tyrrell DL; Kumar R; Agrawal B
J Med Chem; 2006 Mar; 49(6):2049-54. PubMed ID: 16539393
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus mutations associated with antiviral therapy.
Bartholomeusz A; Locarnini S
J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
[TBL] [Abstract][Full Text] [Related]
24. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi.
Teng X; Xu WZ; Hao ML; Fang Y; Zhao YX; Chen SJ; Li D; Gu HX
J Virol Methods; 2010 Sep; 168(1-2):6-12. PubMed ID: 20403386
[TBL] [Abstract][Full Text] [Related]
25. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
26. Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case.
Bottecchia M; Ikuta N; Niel C; Araujo NM; O KM; Gomes SA
J Gastroenterol Hepatol; 2008 Jan; 23(1):67-72. PubMed ID: 18171343
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of HBV surface antigen gene expression by a lentiviral microRNA-based system inhibits HBV replication and HCC growth.
Xiangji L; Feng X; Qingbao C; Weifeng T; Xiaoqing J; Baihe Z; Feng S; Hongyang W; Mengchao W
J Viral Hepat; 2011 Sep; 18(9):653-60. PubMed ID: 20642484
[TBL] [Abstract][Full Text] [Related]
28. Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro.
Luber B; Arnold N; Stürzl M; Höhne M; Schirmacher P; Lauer U; Wienberg J; Hofschneider PH; Kekulé AS
Oncogene; 1996 Apr; 12(8):1597-608. PubMed ID: 8622879
[TBL] [Abstract][Full Text] [Related]
29. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
30. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma.
Lin CL; Liu CH; Chen W; Huang WL; Chen PJ; Lai MY; Chen DS; Kao JH
J Gastroenterol Hepatol; 2007 Jul; 22(7):1098-103. PubMed ID: 17608857
[TBL] [Abstract][Full Text] [Related]
31. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis.
Zheng J; Jiang S; Lu F
Jpn J Infect Dis; 2016 Jul; 69(4):306-13. PubMed ID: 26567840
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT.
Luan F; Liu H; Gao L; Liu J; Sun Z; Ju Y; Hou N; Guo C; Liang X; Zhang L; Sun W; Ma C
Gut; 2009 Nov; 58(11):1528-37. PubMed ID: 19651630
[TBL] [Abstract][Full Text] [Related]
33. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
[TBL] [Abstract][Full Text] [Related]
34. Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B.
Yoshida S; Hige S; Yoshida M; Yamashita N; Fujisawa S; Sato K; Kitamura T; Nishimura M; Chuma M; Asaka M; Chiba H
Ann Clin Biochem; 2008 Jan; 45(Pt 1):59-64. PubMed ID: 18275675
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
36. Effects of cell cycle on telomerase activity and on hepatitis B virus replication in HepG2 2.2.15 cells.
Huang YQ; Wang LW; Yan SN; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):543-7. PubMed ID: 15567742
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
38. Real-time PCR detection of multiple lamivudine-resistant mutations with displacing probes in a single tube.
Wen H; Li Q
J Clin Virol; 2007 Apr; 38(4):334-40. PubMed ID: 17329165
[TBL] [Abstract][Full Text] [Related]
39. Immune reactions against hepatitis B viral antigens lead to the rejection of hepatocellular carcinoma in BALB/c mice.
Chen SH; Hu CP; Lee CK; Chang C
Cancer Res; 1993 Oct; 53(19):4648-51. PubMed ID: 8402642
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
